FULC — Fulcrum Therapeutics Share News
0.000.00%
Last trade - 00:00- $280.77m
- -$38.07m
U.S. STOCKS ON THE MOVE-Unity Software, Viking Holdings, Adobe
U.S. STOCKS ON THE MOVE-Gold miners, silver miners, Warner Bros Discovery
Fulcrum Therapeutics tanks as muscle disorder drug fails in late-stage study
U.S. STOCKS ON THE MOVE-Fulcrum Therapeutics, Summit Therapeutics, Signet Jewelers
Fulcrum Therapeutics tanks as muscle disorder drug fails in late-stage study
Fulcrum stock slumps after muscle disorder drug fails in late-stage study (updated)
Fulcrum's muscle disorder drug fails in late-stage study
Fulcrum Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Fulcrum Therapeutics Q2 Basic EPS USD 0.89
Brief: Fulcrum Therapeutics Increased Size Of Board From Eight To Nine Members
U.S. RESEARCH ROUNDUP- Akoya Biosciences, Boston Beer Company, Victory Capital Holdings
U.S. STOCKS ON THE MOVE-Annexon, MKS Instruments, Robinhood
Fulcrum Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
U.S. STOCKS ON THE MOVE-GameStop, AC Immune , Fulcrum Therapeutics
Fulcrum Therapeutics up on licensing deal with Sanofi for muscle disorder drug
Brief: Fulcrum Therapeutics Enters Into A Collaboration And License Agreement With Sanofi
Brief: Fulcrum Therapeutics Q1 Basic EPS USD -0.43
Fulcrum Therapeutics Inc expected to post a loss of 44 cents a share - Earnings Preview
Fulcrum Therapeutics Inc reports results for the quarter ended in December - Earnings Summary